Kamada Ltd., a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, issued a Letter to Shareholders from Amir London, Chief Executive Officer.
March 6, 2024
· 18 min read